COO at Tarsus (NASDAQ: TARS) gets 26,287 common shares from RSUs
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Tarsus Pharmaceuticals, Inc. Chief Operating Officer Seshadri Neervannan reported equity compensation activity tied to restricted stock units. On March 15, 2026, vested RSUs were settled into 26,287 shares of common stock at an exercise price of $0.00 per share.
The RSUs were granted under the Tarsus 2020 Stock Plan across awards from 2022 through 2025, each vesting in four annual 25% installments on March 15, subject to continuous service. After these settlements, Neervannan directly holds 97,104 shares of common stock.
The filing also shows 475 shares of common stock held indirectly by his daughter, with an explicit disclaimer that he does not beneficially own those securities for Section 16 or other purposes.
Positive
- None.
Negative
- None.
Insider Trade Summary
26,287 shares exercised/converted
Mixed
6 txns
Insider
Neervannan Seshadri
Role
Chief Operating Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Restricted Stock Units | 5,097 | $0.00 | -- |
| Exercise | Restricted Stock Units | 8,148 | $0.00 | -- |
| Exercise | Restricted Stock Units | 8,020 | $0.00 | -- |
| Exercise | Restricted Stock Units | 5,022 | $0.00 | -- |
| Exercise | Common Stock | 26,287 | $0.00 | -- |
| holding | Common Stock | -- | -- | -- |
Holdings After Transaction:
Restricted Stock Units — 0 shares (Direct);
Common Stock — 97,104 shares (Direct);
Common Stock — 475 shares (Indirect, By daughter)
Footnotes (1)
- The shares were issued pursuant to settlement of vested Restricted Stock Units ("RSUs"). This holding balance is related to the Reporting Person's daughter who shares the Reporting Person's household. The Reporting Person disclaims beneficial ownership of the securities held by his daughter, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the securities for purposes of Section 16 or for any other purposes. Each Restricted Stock Unit represents a contingent right to receive one share of the Company's common stock. RSUs granted on March 9, 2022, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. 25% of the RSUs vested on March 15th of each of 2023, 2024, 2025 and 2026. RSUs granted on March 8, 2023, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. 25% of the RSUs will vest on March 15th of each of 2024, 2025, 2026 and 2027, subject to the Reporting Person's continuous service. RSUs granted on March 7, 2024, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. 25% of the RSUs will vest on March 15th of each of 2025, 2026, 2027 and 2028, subject to the Reporting Person's continuous service. RSUs granted on March 5, 2025, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. 25% of the RSUs will vest on March 15th of each of 2026, 2027, 2028 and 2029, subject to the Reporting Person's continuous service.
FAQ
What insider transaction did Tarsus (TARS) report for its COO?
Tarsus reported its COO, Seshadri Neervannan, settled vested restricted stock units into 26,287 shares of common stock. These equity awards are part of long-term compensation, granted under the 2020 Stock Plan with multi-year annual vesting tied to continued service.
Were the Tarsus (TARS) COO’s transactions open-market buys or sales?
The reported transactions were not open-market buys or sales; they were exercises of restricted stock units converting into 26,287 common shares at $0.00 per share. This represents routine settlement of vested equity awards, rather than discretionary trading in the public market.
What do the Tarsus (TARS) RSU footnotes say about vesting?
Footnotes state RSUs granted in 2022, 2023, 2024 and 2025 each vest 25% on March 15 over four consecutive years, contingent on continuous service. Each RSU converts into one common share when vested, explaining the COO’s March 15, 2026 share issuance.